Davin Cho
Founder & CEO

Miraei provides an AI‑driven platform that continuously monitors global oncology trial registries, regulatory filings, and biomarker data, automatically flagging relevant events and scoring their strategic relevance. The system delivers real‑time alerts, natural‑language query capabilities, and predictive guidance to help pharma and biotech market intelligence teams prioritize assets and adjust development plans.
Founder & CEO
Co-founder & CTO
Co-founder
Life‑science market intelligence teams must manually track thousands of oncology clinical trials, regulatory updates, and biomarker strategies, which is time‑consuming and prone to missed competitive signals.
Miraei offers an AI‑driven platform that continuously scans global oncology trial data, regulatory filings, and biomarker information. Ambient agents automatically flag relevant events, assign strategic fit scores, and generate biomarker gap analyses. Users can query the system in natural language to retrieve competitive timelines, efficacy comparisons, or assay usage across trials. The platform translates raw signals into concise strategic insights and next‑action recommendations, helping teams prioritize assets and adjust development plans in real time. All insights are delivered through an integrated command center that unifies data gathering, analysis, and predictive guidance.
Primary customers are market intelligence, competitive analysis, and portfolio strategy teams within pharmaceutical and biotech companies developing oncology therapeutics.